居家存活天数指标与患者及照护者报告结局的并发效度评估
本研究基于两个Kaiser Permanente区域比较两种居家姑息治疗模式的研究数据,纳入3533例重病患者及463名照护者,评估居家存活天数(DAH)与患者及照护者报告结局(PROs)临床显著变化之间的并发效度。结果显示DAH与症状负担改善或维持以及照护准备度变化呈弱相关,提示DAH与患者症状负担的临床重要改善或维持存在关联但强度较弱。
要点
- DAH与ESAS症状负担变化呈弱负相关(r=-0.11至-0.21)。
- DAH与照护准备度变化呈弱正相关(r=0.23-0.24)。
- DAH在症状改善或不变的患者中最高,但组间平均差异未超过0.3个标准差。
核心结论
- 在多样化重病患者人群中,DAH测量与患者症状负担的临床重要改善或维持存在关联,但关联强度较弱。
研究设计与样本
- 研究数据来自一项比较两种居家姑息治疗模式的研究,覆盖两个Kaiser Permanente区域(南加州和西北部)。
- 纳入18岁及以上患者3533例及对应照护者463名。
- 根据ESAS症状负担或CPS照护准备度从基线至1个月的变化,将患者和照护者分为改善、恶化或无变化三组。
- 测量入住居家姑息治疗后30、60、90和180天四个时间窗内的DAH,采用双因素方差分析比较各组DAH。
主要发现
- 校正后两两比较显示,ESAS评分改善或无变化的患者DAH最高,症状恶化者DAH较低。
- 组间平均差异范围从不到1天到约3周,但均未超过0.3个标准差。
- ESAS变化评分与DAH测量呈弱负相关(r=-0.11至-0.21)。
- CPS变化评分与DAH测量呈弱正相关(r=0.23-0.24)。
临床怎么用
- DAH可作为与患者症状负担改善或维持 weakly 相关的结局指标,但不宜单独作为临床决策的主要依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most patients living with serious illness value spending time at home. Emerging data suggest that days alive and at home (DAH) may be a useful metric, however more research is needed. We aimed to assess the concurrent validity of DAH with respect to clinically significant changes in patient- and caregiver-reported outcomes (PROs). METHODS: We drew data from a study that compared two models of home-based palliative care among seriously ill patients and their caregivers in two Kaiser Permanente regions (Southern California and Northwest). We included participants aged 18 years or older (n = 3533) and corresponding caregivers (n = 463). We categorized patients and caregivers into three groups based on whether symptom burden (Edmonton Symptom Assessment System, ESAS) or caregiving preparedness (Preparedness for Caregiving Scale, CPS) showed improvements, deterioration, or no change from baseline to 1 month later. We measured DAH across four time windows: 30, 60, 90, and 180 days, after admission to home palliative care. We used two-way ANOVA to compare DAH across the PRO groups. RESULTS: Adjusted pairwise comparisons showed that DAH was highest for patients whose ESAS scores improved or did not change compared with those with worsening symptoms. Although the mean differences ranged from less than a day to about 3 weeks, none exceeded 0.3 standard deviations. ESAS change scores had weak negative correlations (r = -0.11 to -0.21) with DAH measures. CPS change scores also showed weak, positive correlations (r = 0.23-0.24) with DAH measures. CONCLUSION: DAH measures are associated, albeit weakly, with clinically important improvement or maintenance of patient symptom burden in a diverse, seriously ill population.
引用
- Shen E, Rozema EJ, Haupt EC, et al. Assessing the concurrent validity of days alive and at home metric. J Am Geriatr Soc. 2021. PMID: 34676885. doi:10.1111/jgs.17506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。